#FDA approval

The checkpoint inhibitor delayed disease progression and improved overall survival in non-small-cell lung cancer patients.

Nearly a quarter of patients treated with the peptide-drug conjugate experienced partial remission.

The Johnson & Johnson vaccine, which is easier to store and deliver, will help speed up the coronavirus vaccine rollout.

Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.

About a quarter of patients with advanced skin cancer experienced tumor shrinkage in a clinical trial.

Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.

Umbralisib led to remission in 49% of patients with marginal zone lymphoma and 43% of those with follicular lymphoma.

The new targeted therapy was approved for non-small-cell lung cancer with a specific MET mutation.

The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.

More than 80% of pediatric patients experienced complete remission in a small study.

The antibody-drug conjugate improved response rates and survival compared with chemotherapy.

COVID-19, FDA drug approvals and new approaches to treatment and quality of life stood out among this year’s top stories.

Orgovyx (relugolix) may eliminate some patients’ need to visit a clinic for treatments administered by a health care provider.

Tagrisso (osimertinib) was approved for non-small cell lung cancer patients with EGFR-positive tumors.

Xpovio (selinexor) was approved for adults with multiple myeloma who have received at least one prior therapy.